

DAFTAR PUSTAKA

1. Yolanda fenni, Hartono rudi. Pusat Rehabilitasi Kanker Pasca Pengobatan Pada Wanita Di Banjarmasin. kesehatan. 2022 Aug; 11:1–1.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3).
3. Globocan. Cancer Incident in Indonesia. International Agency for Research on Cancer. 2020;858.
4. Zhao Y, Wang Y, Ma S. Racial Differences in Four Leukemia Subtypes: Comprehensive Descriptive Epidemiology. *Sci Rep.* 2018;8(1).
5. Fadjari H, Sukrisman L. Buku Ajar Ilmu Penyakit Dalam Edisi Keenam. 6th ed. Sudoyo A, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Jakarta: Pusat Penerbit Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2014. 2687–2687 p.
6. Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. *Exp Hematol Oncol.* 2020 Jun 19;9(1).
7. American Cancer Society. Key Statistics for Chronic Myeloid Leukemia. Nih. 2019.
8. Rajabto W, Reksodiputro AH, Rinaldi I, Tadjoeidin H, Priantono D, Angkasa YK. Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia. *Siriraj Med J.* 2022 Aug 1;74(8):530–6.
9. American Cancer Society. What Is Chronic Myeloid Leukemia? What is leukemia? American Cancer Society. 2018.
10. Steegmann JL, Requena MJ, Martín-Regueira P, De la Cámara R, Casado F, Rodriguez Salvanes F, et al. High incidence of autoimmune

- alterations in chronic myeloid leukemia patients treated with interferon- α . *Am J Hematol.* 2003;72(3).
11. Zago Novaretti MC, Fonseca GHH, Conchon M, Dorlhiac-Llacer PE, Fischer Chamone DDA. First case of immune-mediated haemolytic anaemia associated to imatinib mesylate. *Eur J Haematol.* 2003;71(6).
 12. Sari TA, Rofinda ZD, Yusri E. Gambaran Hasil Coomb's Test pada Pasien Keganasan Hematologi di RSUP Dr. M. Djamil Padang. 2022;45(2):160–6. Available from: <http://jurnalmka.fk.unand.ac.id>
 13. Mulyantari N, Yasa I. *Laboratorium Pratransfusi Up Date*. 1st ed. Jiwa atmaja, editor. bali: Udayana University Press; 2016. 104–105 p.
 14. Yassin MA, Hamamyh T. Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia from Busulfan to the Era of Tyrosine Kinase Inhibitors. *Blood.* 2019;134(Supplement_1).
 15. Ning L, Hu C, Lu P, Que Y, Zhu X, Li D. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. *Exp Hematol Oncol.* 2020 Dec 1;9(1).
 16. *Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML)*. National Cancer Institute.
 17. Reksodiputro AH, Atmakusuma TD, Hantoro IF, Rebecca R V. Poster Chronic Myeloid Leukemia in Indonesia.
 18. Baccarani M, Dreyling M. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology.* 2010;21(SUPPL. 5).
 19. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Vol. 94, *Annals of Hematology.* Springer Verlag; 2015. p. 241–7.
 20. Rohrbacher M, Hasford J. Etiology and epidemiology of chronic myeloid leukemia. In: *Neoplastic Diseases of the Blood*. Springer New York; 2013. p. 11–7.
 21. Nuriy R, Iswandari AS, Sarwandi D. Science Midwifery Priapism in Chronic Myeloid Leukemia: A Rare Case [Internet]. Vol. 10, *Science*

- Midwifery. Online; 2022. Available from: www.midwifery.iocspublisher.orgJournalhomepage:www.midwifery.iocspublisher.org
22. Chereda B, Melo J V. Natural course and biology of CML. Vol. 94, *Annals of Hematology*. Springer Verlag; 2015. p. 107–21.
 23. Silver RT. Chronic myeloid leukemia. Vol. 17, *Hematology/Oncology Clinics of North America*. W.B. Saunders; 2003. p. 1159–73.
 24. Shanmuganathan N, Branford S. The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event? Vol. 14, *Current Hematologic Malignancy Reports*. Springer; 2019. p. 501–6.
 25. Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The philadelphia chromosome in leukemogenesis. Vol. 35, *Chinese Journal of Cancer*. BioMed Central Ltd.; 2016.
 26. Tabassum N, Saboor M, Ghani R, Moinuddin M. Heterogeneity of breakpoint cluster region-Abelson (BCR-ABL) rearrangement in patients with chronic myeloid leukemia. *Pak J Med Sci*. 2014;30(4).
 27. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. *Arch Iran Med*. 2008;11(3).
 28. Quintás-Cardama A, Cortes JE. Chronic myeloid leukemia: Diagnosis and treatment. In: *Mayo Clinic Proceedings*. Elsevier Ltd; 2006. p. 973–88.
 29. Kaushansky K, Prchal JT, Press OW, Lichtman MA, Levi M, Burns LJ, et al. *Williams Hematology*. 9th ed. McGraw Hill / Medical; 2015. 1460–1475 p.
 30. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. *Am J Hematol*. 2014;89(5).
 31. Dan L L. *Harrison's Hematology and Oncology*. 2nd ed. 2013. 175–181 p.

32. Sossa Melo CL, Orozco Orozco CA, Peña Castellanos AM, Rueda Perea MA, Porras Bueno CO, Romero Diaz CI, et al. Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature. *Clin Case Rep*. 2021 Nov 1;9(11).
33. Etten RA Van. *Clinical manifestations and diagnosis of chronic myeloid leukemia*. 2022.
34. Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2017;28:iv41–51.
35. Bakta IM. *Hematologi Klinik Ringkas*. Jakarta: EGC; 2006.
36. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. *Am J Hematol*. 2020 Jun 1;95(6):691–709.
37. Sabatine MS. *Pocket Medicine*. 8th ed. Wolters Kluwer; 2022. 366–368 p.
38. Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2012;23(SUPPL. 7).
39. Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Vol. 49, *Blood Reviews*. Churchill Livingstone; 2021.
40. Kristina Gregory N, Hema Sundar O, Maness L, Buffett P, Mead M, Metheny L, et al. NCCN Guidelines Version 2.2022 Chronic Myeloid Leukemia Continue NCCN Guidelines Panel Disclosures Bone marrow transplantation Hematology/Hematology oncology Internal medicine Medical oncology Pathology [Internet]. 2021. Available from: <https://www.nccn.org/home/member->
41. Cortes J, Pavlovsky C, Saúzele S. Chronic myeloid leukaemia. Vol. 398, *The Lancet*. Elsevier B.V.; 2021. p. 1914–26.

42. Eden RE, Coviello JM. Cancer, Leukemia, Myelogenous, Chronic (CML, Chronic Granulocytic Leukemia). StatPearls. 2018.
43. Hamamyh T, Yassin MA. Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia. *Pharmacology*. 2020 Nov 1;105(11–12):630–8.
44. Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, et al. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: Analysis of 533 adult patients who underwent transplantation at king's college hospital. *Biology of Blood and Marrow Transplantation*. 2015 Jan 1;21(1):60–6.
45. Hamamyh T, Yassin MA. Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report. *Clin Med Insights Blood Disord*. 2019;12.
46. Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of Imatinib on Normal Hematopoiesis and Immune Activation. *Stem Cells*. 2005 Sep;23(8):1082–8.
47. Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. The Kinase Inhibitor Imatinib-An Immunosuppressive Drug? Vol. 7, *Current Cancer Drug Targets*. 2007.
48. Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia. Vol. 42, *Transfusion Medicine and Hemotherapy*. S. Karger AG; 2015. p. 287–93.
49. Eşkazan AE. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest? Vol. 85, *British Journal of Clinical Pharmacology*. Blackwell Publishing Ltd; 2019. p. 2241–3.
50. Wardrop KJ, Wilkerson MJ, Mastrorilli C. Testing for Immune-Mediated Hematologic Disease. In: *Schalm's Veterinary Hematology*, Seventh Edition. 2020.
51. Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Vol. 76, *Ulster Medical Journal*. 2007.

52. Vmnis. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.
53. Walters MC, Abelson HT. Pediatric Hematology Interpretation of The Complete Blood Count.
54. Depkes. Klasifikasi Umur Menurut Kategori. Am J Res Commun. 2009;5(August).
55. Garg S, Sharma V, Kumar R, Kumar L, Chopra A. Rapid Onset Anemia in Chronic Myeloid Leukemia Due to Red Cell Agglutination: A Rare Occurrence. Vol. 34, Indian Journal of Hematology and Blood Transfusion. Springer; 2018. p. 758–9.
56. Köksal A, Özatlı D, Ibrahim Haznedaro Ae Glu ÇÇ, Sunguro Glu AA, Karaku S, Büyüka Y. Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t(7;14) anomaly after 5 years of interferon alpha treatment. Vol. 32, Haematologia. 2002.
57. Maldonado NI, Haddock J, Pérez-Santiago E. Autoimmune hemolytic anemia in chronic granulocytic leukemia. Blood. 1967;30(4).
58. Theis SR, Hashmi MF. Coomb's Test. 2023.
59. Jinna S, Khandhar PB. Hydroxyurea Toxicity. StatPearls. 2019.
60. Cornelisse AC, Bergkamp FJM, Griffioen-Keijzer A. Haemolytic anaemia: an unrecognised side effect of hydroxyurea? Vol. 188, British Journal of Haematology. 2020.
61. Rendra M, Yaswir R, Hanif AM. Gambaran Laboratorium Leukemia Kronik di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2013;2(3).
62. Suega K. Aplikasi Klinis Retikulosit. Jurnal Penyakit Dalam. 2010;11(3).
63. Ilander M, Mustjoki S. Immune control in chronic myeloid leukemia. Vol. 8, Oncotarget. 2017.
64. Curran EK, Godfrey J, Kline J. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Vol. 38, Trends in Immunology. 2017.

65. Oktomalioputri B, Mahata LE, Irrahmah M, Yulistini, Rusdji SR, Dermawati, et al, editors. Panduan Penulisan Skripsi Program Studi Kedokteran Fakultas Kedokteran Universitas Andalas. Padang : Fakultas Kedokteran Universitas Andalas; 2022.

